Biodexa Pharmaceuticals Files 6-K Report

TL;DR

Biodexa Pharma (fka Midatech) filed a 6-K on Jan 17, 2025. Standard reporting.

AI Summary

Biodexa Pharmaceuticals Plc (formerly Midatech Pharma Plc) filed a Form 6-K on January 17, 2025. The filing is a report of a foreign private issuer for the month of January 2025. Biodexa Pharmaceuticals is incorporated in the UK and its principal executive offices are located in Cardiff.

Why It Matters

This filing indicates ongoing reporting compliance for Biodexa Pharmaceuticals Plc, a UK-based pharmaceutical company, which is important for investors tracking its regulatory status.

Risk Assessment

Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain significant new financial or operational information.

Key Players & Entities

• Biodexa Pharmaceuticals Plc (company) — Filer of the report
• Midatech Pharma Plc (company) — Former name of the registrant
• January 2025 (date) — Reporting period
• 001-37652 (other) — Commission File Number

FAQ

Key Financial Figures

• $35 million — rchaser is obligated to purchase, up to $35 million of newly issued shares (the “Purc
• $875,000 — agreed to pay to the Purchaser a fee of $875,000 in cash (the “Commitment Fee&rdqu
• $612,500 — uo;Commitment Fee”), of which (i) $612,500 shall be paid to the Purchaser concurre
• $1.00 — ary Shares was equal to or greater than $1.00 (the “Purchase Date”), the
• $200,000 — uo;Fixed Purchase”) not to exceed $200,000, at a purchase price equal to the lesse
• $2,500,000 — e Purchaser to the Company that exceeds $2,500,000, unless such limitation is waived by th

Filing Documents

• y1162546k.htm (6-K) — 29KB
• ex10_1.htm (EX-10.1) — 241KB
• ex10_2.htm (EX-10.2) — 95KB
• 0001214659-25-000919.txt ( ) — 367KB

01. Entry into Material Definitive Agreement

Item 1.01. Entry into Material Definitive Agreement. Securities Purchase Agreement On January 17, 2025, Biodexa Pharmaceuticals Plc (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with C/M Capital Master Fund, LP (the “Purchaser”), pursuant to which the Company, subject to the restrictions and satisfaction of the conditions in the Purchase Agreement, has the right, but not the obligation, to sell to the Purchaser, and the Purchaser is obligated to purchase, up to $35 million of newly issued shares (the “Purchase Shares”) of the Company’s American Depositary Shares (the “Depositary Shares”), each representing 10,000 of the Company’s ordinary shares, nominal value £0.00005 each (the “Ordinary Shares”). As consideration for the Purchaser’s execution and delivery of the Purchase Agreement, the Company has agreed to pay to the Purchaser a fee of $875,000 in cash (the “Commitment Fee”), of which (i) $612,500 shall be paid to the Purchaser concurrently with the execution of the Purchase Agreement and (ii) the balance of such Commitment Fee shall be paid to the Purchaser, in a pro rata fashion, simultaneously with the delivery of any Purchase Shares under the Purchase Agreement (each, a “Commitment Fee Payment Date”). If the Company were to fail to pay the applicable portion of the Commitment Fee to the Purchaser on the applicable Commitment Fee Payment Date, the Company has the right, in its sole discretion, to issue Depositary Shares representing the value of the applicable portion of the Commitment Fee (the “Commitment Shares,” and together with the Purchase Shares, the “Securities”) to release the Company of its liability to pay the Commitment Fee, valued at the closing sale price of the Depositary Shares on the trading day immediately prior to the date of the Purchase Agreement. The

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Biodexa Pharmaceuticals PLC Date: January 17, 2025 By: /s/ Stephen Stamp Stephen Stamp Chief Executive Officer and Chief Financial Officer 5

View Full Filing

View this 6-K filing on SEC EDGAR